$36.41
0.130.36%
Ult. Agg.: Nov 2, 6:25 PM
Indivior Pharmaceuticals Inc Ordinary Share (INDV) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $1.32 | $1.08 | 22.2 % |
| Q2 | Aug 3, 2026 | $1.15 | $0.92 | 25.0 % |
| Q1 | Apr 30, 2026 | $0.96 | $0.66 | 45.5 % |
| Q4 | Feb 26, 2026 | $0.82 | $0.66 | 24.2 % |
Quarterly Revenue (Billions)
Indivior Pharmaceuticals Inc Ordinary Share (INDV) ha pubblicato l'ultima guidance il ottobre 29, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $1.29B - $1.36B per il periodo.
Rispetto alle previsioni precedenti, Indivior Pharmaceuticals Inc Ordinary Share ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Indivior Pharmaceuticals Inc Ordinary Share ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Indivior Pharmaceuticals Inc Ordinary Share. 18
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.08 | $0.92 | $0.66 | $0.66 |
| Actual | $1.32 | $1.15 | $0.96 | $0.82 |
| Surprise | +22.2% | +25.0% | +45.5% | +24.2% |
| Revenue | ||||
| Estimate | $328.8M | $306.8M | $272.0M | $305.5M |
| Actual | $356.0M | $343.0M | $317.0M | $358.0M |
| Surprise | +8.27% | +11.8% | +16.5% | +17.2% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $1.19 | $0.95 |
| Revenue | ||
| Consensus | $336.6M | $328.0M |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $356.00M | $328.82M | 8.27 % |
| Q2 | Aug 3, 2026 | $343.00M | $306.84M | 11.8 % |
| Q1 | Apr 30, 2026 | $317.00M | $272.00M | 16.5 % |
| Q4 | Feb 26, 2026 | $358.00M | $305.46M | 17.2 % |